Hikma Pharmaceuticals Management
Management criteria checks 4/4
Hikma Pharmaceuticals' CEO is Said Samih Darwazah, appointed in Dec 2025, has a tenure of less than a year. total yearly compensation is $3.08M, comprised of 33.8% salary and 66.2% bonuses, including company stock and options. directly owns 0.76% of the company’s shares, worth $32.54M. The average tenure of the management team and the board of directors is 2.3 years and 4.9 years respectively.
Key information
Said Samih Darwazah
Chief executive officer
US$3.1m
Total compensation
| CEO salary percentage | 33.79% |
| CEO tenure | less than a year |
| CEO ownership | 0.8% |
| Management average tenure | 2.3yrs |
| Board average tenure | 4.9yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2025 | US$3m | US$1m | US$402m |
| Sep 30 2025 | n/a | n/a | US$387m |
| Jun 30 2025 | n/a | n/a | US$371m |
| Mar 31 2025 | n/a | n/a | US$365m |
| Dec 31 2024 | US$4m | US$1m | US$359m |
| Sep 30 2024 | n/a | n/a | US$322m |
| Jun 30 2024 | n/a | n/a | US$285m |
| Mar 31 2024 | n/a | n/a | US$238m |
| Dec 31 2023 | US$4m | US$1m | US$190m |
| Sep 30 2023 | n/a | n/a | US$168m |
| Jun 30 2023 | n/a | n/a | US$146m |
| Mar 31 2023 | n/a | n/a | US$167m |
| Dec 31 2022 | US$3m | US$1m | US$188m |
| Sep 30 2022 | n/a | n/a | US$267m |
| Jun 30 2022 | n/a | n/a | US$346m |
| Mar 31 2022 | n/a | n/a | US$384m |
| Dec 31 2021 | US$5m | US$1m | US$421m |
| Sep 30 2021 | n/a | n/a | US$444m |
| Jun 30 2021 | n/a | n/a | US$467m |
| Mar 31 2021 | n/a | n/a | US$449m |
| Dec 31 2020 | US$3m | US$1m | US$431m |
| Sep 30 2020 | n/a | n/a | US$472m |
| Jun 30 2020 | n/a | n/a | US$513m |
| Mar 31 2020 | n/a | n/a | US$500m |
| Dec 31 2019 | US$4m | US$1m | US$486m |
Compensation vs Market: Said Samih's total compensation ($USD3.08M) is below average for companies of similar size in the US market ($USD6.98M).
Compensation vs Earnings: Said Samih's compensation has been consistent with company performance over the past year.
CEO
Said Samih Darwazah (69 yo)
H.E. Engineer Said Samih Taleb Darwazah is CEO of Hikma Pharmaceuticals PLC from December 2025. He is Vice Chairman of the Board of Capital Bank of Jordan from June 14, 2021. Engineer Darwazah joined the C...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | less than a year | US$3.08m | 0.76% $ 32.5m | |
| Executive Vice Chairman & Deputy CEO of MENA | 20.8yrs | US$3.26m | 0.91% $ 39.0m | |
| Deputy CEO of North America and Europe & Director | less than a year | US$43.54k | 0.25% $ 10.8m | |
| VP, Group Financial Controller & Acting CFO | less than a year | no data | no data | |
| Chief Information Officer | no data | no data | no data | |
| Associate Director of Investor Relations | no data | no data | no data | |
| General Counsel | no data | no data | no data | |
| Executive Vice President of Corporate Development and M&A | 12.3yrs | no data | 0.28% $ 12.2m | |
| Chief People Officer | 2.8yrs | no data | no data | |
| Executive Vice President of Strategic Planning & Global Affairs | 8.4yrs | no data | no data | |
| Senior Vice President of Corporate Quality Compliance/Health & Safety | 2.3yrs | no data | no data | |
| Senior Vice President of Corporate Quality Compliance | no data | no data | no data |
Experienced Management: HKMP.F's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Vice Chairman & Deputy CEO of MENA | 20.8yrs | US$3.26m | 0.91% $ 39.0m | |
| Deputy CEO of North America and Europe & Director | less than a year | US$43.54k | 0.25% $ 10.8m | |
| Independent Chairman | 3.6yrs | US$172.10k | 0.0096% $ 411.0k | |
| Non-Executive Director | 20.7yrs | US$120.78k | 0.57% $ 24.4m | |
| Senior Independent Director | 6.1yrs | US$158.91k | 0.0021% $ 90.3k | |
| Independent Non-Executive Director | 3.6yrs | US$156.60k | 0.00047% $ 20.1k | |
| Independent Non-Executive Director | 7yrs | US$159.96k | 0.00052% $ 22.3k | |
| Chairman of West-ward Pharmaceuticals | no data | no data | no data | |
| Independent Non-Executive Director | 3.7yrs | US$141.70k | 0.0016% $ 70.2k |
Experienced Board: HKMP.F's board of directors are considered experienced (4.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/24 07:22 |
| End of Day Share Price | 2026/06/03 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hikma Pharmaceuticals PLC is covered by 27 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sidhartha Modi | Barclays |
| James Gordon | Barclays |
| Beatrice Fairbairn | Berenberg |